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Abstract
Tardive dyskinesia (TD) is an important limiting factor in the use of typical antipsychotic drugs. Genetic
variability in the serotonin 2A (5-HT2A) receptor may inﬂuence risk for TD but the results of prior studies
are not conﬁrmatory. The objective of this study was to determine association of T102C and His452Tyr
polymorphisms in the 5-HT2A receptor gene (HTR2A) with TD in a large, multicentre patient sample. The
design employed case-control analysis controlling for possible confounders using pooled, original data
from published and available unpublished samples and employing logistic regression, analysis of vari-
ance and meta-analysis. The study sample consisted of 635 patients with schizophrenia or schizoaﬀective
disorder (256 with TD and 379 without TD) drawn from ﬁve research centres, divided into six groups
based on population origin. The main outcome measure was association of a categorical diagnosis of TD
based on the Research Diagnostic Criteria for TD with HTR2A T102C and His452Tyr genotypes and
haplotypes. The ﬁndings indicate signiﬁcant association of TD with HTR2A T102C genotype (p=0.002)
over and above the eﬀect of population group, also when controlling for age and gender (p=0.0008), but
not with His452Tyr genotype. The T102C genotype was signiﬁcantly associated with TD in older
(>median age 47 yr, p=0.002) but not younger patients and in patients with non-orofacial (limb-truncal)
(p=0.001) but not orofacial TD. By meta-analysis the Mantel–Haenszel (M-H) pooled odds ratio (OR)
across all the available data was 1.64. A T102C-His452Tyr haplotype was signiﬁcantly associated with TD
(p=0.0008). These ﬁndings conﬁrm that genetic variability in HTR2A contributes a small but signiﬁcant
degree of risk for the expression of TD, particularly in older patients and speciﬁcally for the non-orofacial
(limb-truncal) type. Together with other genetic variants associated with TD the ﬁndings could be used to
assess risk in patients who are candidates for treatment with typical antipsychotic medications.
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Introduction
Tardive dyskinesia (TD) is a potentially irreversible,
iatrogenic movement disorder that aﬀects 20–50% of
patients receiving long-term antipsychotic treatment
with dopamine D2 receptor blocking drugs (Kane and
Smith, 1982 ; Tamminga and Woerner, 2002). Atypical
antipsychotic drugs that have a low propensity to
induce TD are now widely used (Caroﬀ et al., 2002;
Correll et al., 2004). Nevertheless, classical anti-
psychotic agents are still extensively prescribed,
primarily for economic reasons (Emsley et al., 1999).
Furthermore, there is growing concern about the
adverse eﬀects of atypical antipsychotic drugs on body
weight and glucose-lipid metabolism (American
Diabetes Association et al., 2004). It would be of great
value to clinicians to have the option of prescribing
typical antipsychotics by being able to exclude
patients at risk for TD.
Age is the strongest known risk factor for the
development of TD (Smith and Baldessarini, 1980;
Woerner et al., 1998). Other factors include duration
and intensity of prior exposure to antipsychotic
medication, female gender, organic brain abnormali-
ties, smoking, race and aﬀective disorder (Eastham
et al., 1996 ; Kane and Smith, 1982 ; Kane et al, 1992;
Yassa and Jeste, 1992). A genetic component in the
susceptibility to TD is suggested by clinical reports of
aggregation of TD cases in families (Waddington and
Youssef, 1988; Weinhold et al., 1981 ; Yassa and
Ananth, 1981 ; Youssef et al., 1989). Strain diﬀerences
in the susceptibility of rats to antipsychotic-induced
repetitive jawmovements (RJM) and vacuous chewing
(Rosengarten et al., 1994 ; Tamminga et al., 1990) and
diﬀerences among mice strains in up-regulation of
striatal dopamine receptors after exposure to dopa-
mine D2 receptor blockers (Belmaker et al., 1981)
provide support for a genetic predisposition.
Although the exact mechanism of TD remains un-
clear, it is believed that the nigrostriatal dopaminergic
tract, which is pivotally involved in the regulation of
motor behaviour, may play a key role (Tamminga and
Woerner, 2002). The high binding aﬃnity of typical
antipsychotic drugs for dopamine D2 receptors
resulting in their up-regulation post-synaptically, is
thought to contribute to nigrostriatal dopaminergic
overactivity. Several studies have examined the
role of dopaminergic receptor and transporter poly-
morphisms in susceptibility to TD as well enzymes
relevant to dopaminergic function (Segman et al.,
2003 ; Segman and Lerer, 2002a). For the most part
the results have been negative, with one notable
exception – the dopamine D3 receptor gene (DRD3).
A relatively large number of studies have focused on a
polymorphic site at position 9 of the ﬁrst exon of
DRD3 that gives rise to a serine (Ser) to glycine (Gly)
substitution in the N-terminal extracellular domain of
the receptor (Lannfelt et al., 1992). Lerer et al. (2002)
published the ﬁrst pooled andmeta-analysis of studies
on DRD3 and TD, ﬁnding a signiﬁcant association
with DRD3Gly. Reports published since then further
implicate DRD3 in susceptibility to TD (Chong et al.,
2003 ; Werge et al., 2003 ; Woo et al., 2002).
Several lines of evidence implicate brain seroto-
nergic systems as possibly modifying susceptibility to
express TD. Dorsal raphe serotonergic projections in-
hibit dopaminergic neuronal activity through 5-HT2A
receptor activation (Kapur and Remington, 1996).
5-HT2A antagonists have been shown to augment endo-
genous striatal dopamine release in vivo (Dewey et al.,
1995). 5-HT2A antagonists reduce neuroleptic-induced
catalepsy (Wadenberg, 1996) as well as neuroleptic-
induced RJM in rodents (Naidu and Kulkarni, 2001)
and atypical antipsychotic agents reduce RJM
(Rosengarten et al., 1999). Long-term exposure to
typical antipsychotics results in 5-HT2A receptor up-
regulation in striatal regions, whereas atypical drugs
with low DRD2/high 5-HT2A receptor occupancy do
not (Kusumi et al., 2000). Finally, long-term elevations
in 5-HT2A receptor binding and mRNA expression
in nigrostriatal regions have been documented in
response to loss of dopamine neurons following
6-hydroxy dopamine administration (Kostrzewa et al.,
1998). Atypical antipsychotic drugs have a lower
propensity to induce TD (Caroﬀ et al., 2002 ; Casey,
1999 ; Correll et al., 2004) and following exposure
to a dopamine D2 receptor blocker show eﬃcacy in
reducing the expression of dyskinesia (Alptekin and
Kivircik, 2002 ; Bassitt and Louza Neto, 1998 ; Lucetti
et al., 2002).
The 5-HT2A receptor gene (HTR2A) is located on
chromosome 13q14-21 (Hsieh et al., 1990). A number
of polymorphic sites have been described in the gene
(Collier et al., 1997 ; Erdmann et al., 1996; Ohara et al.,
1997 ; Warren et al., 1993) of which T102C, A-1438G,
and His452Tyr are common variations. Following the
initial report of Segman et al. (2001), one published
study found an association of T102C with TD (Tan
et al., 2001) while two did not (Basile et al., 2001;
Herken et al., 2003) (Table 1). The two published
studies that examined His452Tyr association with TD
did not ﬁnd a relationship (Basile et al., 2001 ; Segman
et al., 2001). Two studies found T102C and A-1438G to
be in close linkage disequilibrium (LD), Segman et al.
(2001) but not Basile et al. (2001) observing an associ-
ation with TD. Segman and Lerer (2002b) found that
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Table 1. Published studies on HTR2A T102C and other HTR2A polymorphisms and TD
Publication Subjects Findings from categorical analysis Findings from continuous analysis
Other HTR2A polymorphisms
examined
Segman et al. (2001) TD-Y: n=59, age=54.4¡13.0 yr (S.D.)
TD-N: n=62, age=50.5¡10.2 yr (S.D.)
Origin : Israeli Ashkenazi and
Sephardic Jews
Allelic association – excess 102C
allele in TD-Y vs. TD-N and
controls (x2=12.8, d.f. 2, p=0.002)
Genotypic association – excess
102C/C genotypes in TD-Y vs.
TD-N and controls (x2=13.3,
d.f. 4, p=0.01)
Signiﬁcant eﬀect of T102C genotype
on AIMS trunk (F=3.9, d.f. 2, 116 ;
p=0.02) and incapacitation (F=5.0,
d.f. 2, 115, p=0.006) scores, by
ANCOVA controlling for age at
ﬁrst antipsychotic treatment
His452Tyr : no association
with TD
A-1438G: in complete linkage
disequilibrium with T102C
Basile et al. (2001) TD-Y: n=54
TD-N: n=82
Age (combined)= 33.2¡9.1 yr (S.D.)
Origin : Caucasian, n=109,
Afro-American, n=27
No allelic or genotypic association
between HTR2A T102C polymorphism
and TD
No eﬀect of T102C genotype on
AIMS total scores
AIMS subscale scores not reported
His452Tyr : no association
with TD
A-1438G: in strong but not
complete linkage
disequilibrium with T102C
No association with TD
Tan et al. (2001) TD-Y: n=87, age=55.9¡8.4 yr (S.D.)
TD-N: n=134, age=48.7¡9.4 yr (S.D.)
Origin : Singapore Chinese
No allelic association between HTR2A
T102C polymorphism and TD
Genotypic association – excess 102T/C
and 102C/C genotypes in TD-Y vs.
TD-N and controls (x2=18.81,
d.f. 4, p=0.001)
Not reported Not reported
Herken et al. (2003) TD-Y: n=32
TD-N: n=111
Age (combined)= 32.3¡9.1 yr (S.D.)
Origin : Turkish
No allelic or genotypic association
between HTR2A T102C
polymorphism and TD
Not reported A-1438G: no association with TD
AIMS, Abnormal Involuntary Movements Scale ; TD-Y, Tardive dyskinesia positive ; TD-N, tardive dyskinesia negative.
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the association of T102C with TD was demonstrable in
older but not younger patients.
In this paper we present the results of a pooled
analysis of original data from three of the four
published studies on HTR2A and TD as well as two
unpublished samples. Our analysis took into account
the possible confounding eﬀects of population origin,
diﬀerences in the rating of abnormal involuntary
movements among centres and the impact of age
and gender. In addition a meta-analysis was per-
formed that included all the published and unpub-
lished studies.
Materials and methods
Patients and clinical assessment
This project was a collaboration among ﬁve research
centres (Table 2). Data on the Jerusalem (Segman et al.,
2001), Singapore (Tan et al., 2001) and Toronto sam-
ples (Basile et al., 2001) had been published previously
and data on the patients from Milan (Macciardi et al.,
1997) and Vienna (Aschauer et al., 1998) published
in abstract form. The existence of additional studies
was checked by a MEDLINE search that included the
terms tardive dyskinesia, genetics and serotonin 2A
(or 5-HT2A) receptors and by contacting known, active
researchers on the genetics of TD. All the projects were
approved by the local Institutional Review Boards and
the patients gave written, informed consent. Clinical
and genotypic data were supplied by each of the cen-
tres. The minimum criteria for inclusion were infor-
mation on age and gender ; diagnosis of schizophrenia
or schizoaﬀective disorder according to DSM-IV or
ICD-9 ; presence or absence of TD according to the Re-
search Diagnostic Criteria for TD (Schooler and Kane,
1982) and genotypic data for the HTR2A T102C poly-
morphism. Abnormal Involuntary Movement Scale
(AIMS) scores (Guy, 1976) were available the Jeru-
salem, Singapore and Toronto patients. Patients from
the Milan centre were assessed by the Rockland–
Simpson Scale (Cavallaro et al., 1993) and patients
from Vienna by the Tardive Dyskinesia Rating Scale
(Simpson et al., 1979). Since the presence or absence of
TD was based on a single evaluation, the TD diagnosis
is at a probable level according to the RDC-TD
(Schooler and Kane, 1982). The patients from the ﬁve
centres were divided into six groups (Table 2) since
the African-American (A-A) and Caucasian patients
from the Toronto centre were considered separately.
The Jerusalem sample included Jewish patients of
Table 2. Demographic and clinical details of the sample
Group
TD-Y TD-N
Origin
TD
assessmentn Age (yr) Gender n Age (yr) Gender
Jerusalem 59 54.4¡13 F 29 62 50.5¡10.1 F 30 Israeli Ashkenazi (n=71) and AIMS
M 30 M 32 non-Ashkenazi (n=50) Jews
Milan 34 55.8¡10.5 F 16 60 53.4¡10.5 F 31 Northern Italian Caucasian RSDS
M 18 M 29
Singapore 88 55.8¡8.3 F 18 133 48.7¡9.4a F 32 Chinese AIMS
M 70 M 101
Toronto : 14 36.6¡11.9 F 4 13 29.3¡9.8b F 4 African-American AIMS
African-American M 10 M 9
Toronto : 40 35.6¡8.2 F 13 69 31.9¡8.4 F 17 North American Caucasian AIMS
Caucasian M 27 M 52
Vienna 21 36.9¡13.4 F 9 42 31.5¡9.5 F 17 Austrian Caucasian TDRS
M 12 M 25
Groups : Jerusalem (Hadassah – Hebrew University Medical Center, Jerusalem, Israel) ; Milan (IRCCS Hospitale San Raﬀaele,
Vita Salute University, Milan, Italy) ; Singapore (Defence Medical and Environmental Research Institute and Institute of
Mental Health, Singapore) ; Toronto : (Centre for Addiction and Mental Health, University of Toronto, Canada) ; Vienna
(University of Vienna, Austria).
TD-Y, Tardive dyskinesia positive ; TD-N, tardive dyskinesia negative ; SCZ, schizophrenia ; SA, schizoaﬀective ; M, male ;
F, female ; AIMS, Abnormal Involuntary Movements Scale ; RSDS, Rockland and Simpson Dyskinesia Scale ; TDRS, Tardive
Dyskinesia Rating Scale.
a t=5.81, p<0.0001, vs. Singapore TD-Y.
b t=2.26, p=0.02 vs. Toronto Caucasians TD-Y.
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Ashkenazi and Sephardic origin but there was no
signiﬁcant diﬀerence in the frequency of the T102C or
His452Tyr polymorphisms between these groups
(Segman et al., 2001). Patients from Milan and Vienna
were Caucasians of Northern Italian and Austrian
origin respectively and the Singapore patients were of
Chinese extraction.
Genotyping
The T102C and His452Tyr polymorphisms in HTR2A
were genotyped in the laboratories of the ﬁve partici-
pating centres by standard PCR-based methods.
The detailed procedures followed in the Jerusalem
(Segman et al., 2001) Singapore (Tan et al., 2001) and
Toronto laboratories (Basile et al., 2001) are described
in their publications. The same procedures were fol-
lowed in the Milan and Vienna laboratories and in the
Singapore laboratory for His452Tyr (results for which
had not been published previously).
Statistical analysis
Maximum-likelihood x2 statistics were employed
for categorical analyses. For bivariate comparisons
of continuous data the Student’s t test was used and
for multivariate comparisons, analysis of variance
(ANOVA) or covariance (ANCOVA). Multinomial
logistic regression was applied to analyse the eﬀect of
genotypes, considered as multilevel categorical vari-
ables. Two sets of analyses were implemented on the
pooled sample. For the ﬁrst set the outcome (depen-
dent) variable was T102C or His452Tyr genotype. The
covariates of the model were the clinical phenotype of
interest, i.e. TD present or absent and group, given a
possible population eﬀect on genotype. In this case,
the phenotype of interest is a predictor of outcome and
group is a potential confounder. Group was tested by
generating a set of dummy variables equal to the
number of groups included in the sample in order to
evaluate the speciﬁc eﬀect of any group. Results from
the model are presented as likelihood ratio (LR) tests.
In a further set of analyses the outcome variable of the
logistic regression was TD phenotype (present or ab-
sent) and the covariates of the model were age, gender
and HTR2A genotype distribution. The implemen-
tation of these procedures for analysis of genetic
association in samples from multiple centres and of
diﬀerent population origin has described previously
by Lerer et al. (2001, 2002). The STATA 8.0 program
(Stata Corporation, College Station, TX, USA) a gen-
eral package for statistics and genetic epidemiology,
was employed for these analyses and also for themeta-
analysis. p values<0.05 (two-tailed) were regarded as
signiﬁcant. LD between the polymorphisms and
analysis of haplotypes was performed by the program
‘hapipf’, part of STATA 8.0.
Results
Confounding variables and Hardy–Weinberg
equilibrium (HWE)
In order to identify potential confounders in a pooled
analysis of the six patient groups, we initially com-
pared age between patients with (TD-Y) and without
TD (TD-N) across the groups (by ANOVA with group
and TD status as the independent variables). There
were signiﬁcant eﬀects of group (F=94.38, d.f. 5, 622,
p<0.000001) and TD status (F=24.98, d.f. 1, 622,
p=0.000001). Post-hoc Neumann–Keuls tests showed
a clearly bimodal distribution with the patients
from Jerusalem, Milan and Singapore approximately
two decades older than the Toronto A-A, Toronto
Caucasian and Viennese patients (p<0.0001 in all
cases) (Table 2). Comparing TD-Y and TD-N patients
within the groups, TD-Y patients were signiﬁcantly
older in the Singapore (t=5.81, d.f. 219, p<0.000001)
and Toronto Caucasian groups (t=2.26, d.f. 107,
p=0.03) but not in the other groups. There was no
signiﬁcant diﬀerence in gender distribution between
TD-Y and TD-N patients. All the TD-N groups were in
HWE for T102C and His452Tyr (p>0.05). Among the
TD-Y groups, the one from Singapore was not in HWE
(x2=11.92, p=0.0006), due to an excess of hetero-
zygotes. For the His452Tyr polymorphism, only the
Toronto A-A TD-Y group was not in HWE (x2=5.50,
p=0.02), due to a small but signiﬁcant excess of
Tyr-Tyr, homozygotes.
Allele and genotype frequencies within groups
Table 3 shows a comparison of the frequency of T102C
alleles between patients with and without TD in each
of the groups. There was signiﬁcant excess of C alleles
among the TD patients in the Jerusalem (x2=11.28, d.f.
1, p=0.001) and Singapore (x2=4.52, d.f. 1, p=0.03)
groups and a trend in this direction in the Toronto A-A
group (x2=3.87, d.f. 1, p=0.05). Table 3 also shows
HTR2A T102C genotypes in the TD-Y and TD-N
patients of each group. Comparison of genotype
distribution by the STATA 8.0 subroutine ‘genhwcci ’
showed a signiﬁcant diﬀerence in the Jerusalem group
(x2=12.36, d.f. 1, p=0.002) and in the Singapore
group (x2=17.01, d.f. 1, p=0.0002.). In the Jerusalem
group there was an excess of C/C homozygotes in
the TD-Y group (x2=11.45, d.f. 1, p=0.003) and in the
Singapore group (x2=7.23, d.f. 1, p=0.03) an excess of
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T/C heterozygotes among the TD-Y patients. The fre-
quency of the minor 452Tyr allele varied signiﬁcantly
among the ﬁve groups that were assayed (Jerusalem
0.12, Singapore 0.01, Toronto A-A 0.11, Toronto
Caucasians 0.13, Vienna 0.05 ; x2=53.26, d.f. 4,
p<0.000001). There were no signiﬁcant diﬀerences in
His452Tyr allele frequency and genotype distribution
between the TD-Y and TD-N patients in any of the
groups.
Pooled analyses – logistic regressions
Our goal was to evaluate association of the HTR2A
T102C polymorphism with TD while controlling for
potential confounders : (a) diﬀerences among groups
in T102C allele frequency; (b) possible group diﬀer-
ences in the evaluation of TD; (c) the impact of age and
gender. A multinomial logistic regression was per-
formed with the ‘dependent’ variable being T102C
genotype (3 levels) (Table 4). We evaluated the eﬀect
of ‘group’ and ‘TD status’ as predictors of the
dependent variable. The LR test of the two models
(group+TD status and group alone) determines the
signiﬁcance of TD status controlled for the potential
confounding eﬀect of group (Table 4). There was
a signiﬁcant eﬀect of both the T/C (Z=0.43, 95%
CI 0.03–0.81, x2=2.16, p=0.003) and C/C genotypes
(Z=0.14, 95% CIx0.64 to 0.92, x2=3.48, p=0.001) vs.
the T/T genotype. The LR test for TD status was sig-
niﬁcant, while controlling for the possible confound-
ing eﬀect of group (x2=12.46, d.f. 2, p=0.002).
In the second set of logistic regressions the de-
pendent variable was TD status and the predictors
evaluated were age, gender and T102C/C genotype
(Table 5). There was a signiﬁcant eﬀect of age
(p<0.001) and no signiﬁcant eﬀect of gender (p=0.35).
The ‘net’ eﬀect of T102C/C genotype, i.e. the LR test
was again signiﬁcant (x2=11.23, d.f. 1, p=0.0008).
We conducted further, subsidiary analyses in order to
identify the most appropriate genotypic model. A
co-dominant (additive) model yielded x2=9.82, d.f. 1,
p=0.0017. The dominant model was also signiﬁcant
(x2=6.0 d.f.=1, p=0.0093) while the result for a
recessive model was x2=5.59, d.f. 1, p=0.018.
The same set of logistic regressions was conducted
for the His452Tyr polymorphism. There was no evi-
dence for an association between this polymorphism
and TD across the ﬁve groups (data available on
request).
Linkage disequilibrium and haplotypes
To examine the eﬀect of the T102C-His452Tyr
haplotype in TD, we ﬁrst checked whether the two
polymorphisms were in LD in our sample, which we
found to be true (x2=8.11, d.f. 1, p=0.004). Therefore,
we estimated the eﬀect of the haplotype on TD and
found it very signiﬁcant (x2=16.7, d.f. 3, p=0.0008 ; OR
2.8, CI 1.05–12.3) for the TD-Y group with a double risk
allele compared to none.
Role of age in HTR2A-related risk for TD
Given the strong relationship between age and
susceptibility to TD (Kane et al., 1992 ; Smith and
Baldessarini, 1980; Woerner et al., 1998) we had
Table 3. HTR2A T102C allele and genotype frequencies in the individual groups
Group TD status
No.
Patients
Allele freq.
Signiﬁcance
Genotype freq.
Signiﬁcance
T C (ML x2, d.f. 1) T/T T/C C/C (LR x2, d.f. 2)
Jerusalem TD-Y 59 37.3 62.7 11.28 16.1 50 33.9 11.45
TD-N 62 58.9 41.1 p=0.001 42.4 40.7 16.9 p=0.003
Milan TD-Y 34 48.5 51.5 0.40 18.3 56.7 25 0.47
TD-N 60 53.3 46.7 p=0.53 23.5 55.9 20.6 p=0.79
Singapore TD-Y 88 64.4 35.6 4.52 3.8 45.1 51.1 7.23
TD-N 133 73.5 26.5 p=0.03 4.5 62.5 33 p=0.027
Toronto : TD-Y 14 17.9 82.1 3.87 30.8 53.9 15.4 4.23
African-American TD-N 13 42.3 57.7 p=0.049 64.3 35.7 – p=0.121
Toronto : TD-Y 40 52.5 47.5 0.024 21.7 53.6 24.6 0.047
Caucasian TD-N 69 51.4 48.6 p=0.88 20 55 25 p=0.98
Vienna TD-Y 21 54.8 45.2 – 23.8 61.9 14.3 2.10
TD-N 42 54.8 45.2 33.3 42.9 23.8 p=0.35
TD-Y, Tardive dyskinesia positive ; TD-N, tardive dyskinesia negative ; ML, maximum likelihood; LR, likelihood ratio.
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proposed that age might inﬂuence the relationship
between HTR2A and TD (Segman and Lerer, 2002b).
Accordingly we performed subsidiary analyses of the
current dataset in order to test this hypothesis. First,
we re-ran the multinomial logistic regression in which
the dependent variable was the T102C genotype (three
levels) and evaluated the eﬀect of ‘group’ and ‘TD
status’ as predictors of the dependent variable with
the sample divided into older or younger patient
groups based on the median age [younger patients,
f47 yr : Y-TD (n=96), N-TD (n=215) ; older
patients, >47 yr : Y-TD (n=159), N-TD (n=164)]. The
LR test for TD status predicting T102C genotype was
signiﬁcant for the older (x2=13.05, d.f. 2, p=0.002)
but not the younger patients (x2=1.6, d.f. 2, p=0.45).
In a second set of logistic regressions in which the
Table 4.Multinomial logistic regression for variables predicting T102C genotypes in patients with and without TD from the
six groups
Model
(Log-likelihood)
(Model)
x2 (d.f.) Z (d.f.) p value Coeﬃcients Z
Null model x642.79
Model A 595.42
[Genotype T/C] Centre
Jerusalem x1.57 (1) 0.11 x0.65 (x1.46 to 0.16)
Milan x0.68 (1) 0.49 x0.29 (x1.14 to 0.55)
Singapore x2.77 (1) 0.006 x1.03 (x1.77 tox0.3)
Toronto A-A 0.68 (1) 0.49 0.57 (x1.07 to 2.22)
Toronto Caucasian x0.94 (1) 0.34 x0.39 (x1.21 to 0.42)
Vienna* – – –
TD status 2.16 (1) 0.003 0.43 (0.03 to 0.81)
[Genotype C/C] Centre
Jerusalem x0.98 (1) 0.32 x0.45 (x1.37 to 0.45)
Milan x1.23 (1) 0.21 x0.62 (x1.6 to 0.36)
Singapore x5.55 (1) <0.001 x2.92 (x3.95 tox1.9)
Toronto A-A 1.52 (1) 0.13 1.30 (x0.38 to 2.98)
Toronto Caucasian x1.32 (1) 0.18 x0.64 (x1.59 to 0.31)
Vienna* – – –
TD status 3.48 (1) 0.001 0.14 (x0.64 to 0.92)
Model B x601.65
[Genotype T/C] Centre
Jerusalem x1.42 (1) 0.12 x0.58 (x1.39 to 0.22)
Milan x0.65 (1) 0.51 x0.28 (x1.12 to 0.56)
Singapore x2.65 (1) 0.008 x0.99 (x1.72 to 0.26)
Toronto A-A 0.76 (1) 0.44 0.63 (x1.0 to 2.28)
Toronto Caucasian x0.90 (1) 0.36 x0.37 (x1.19 to 0.44)
Vienna – – –
[Genotype C/C] Centre
Jerusalem x0.68 (1) 0.49 x0.31 (x1.21 to 0.58)
Milan x1.17 (1) 0.24 x0.58 (x1.56 to 0.39)
Singapore x5.40 (1) <0.001 x2.81 (x3.8 tox1.8)
Toronto A-A 1.69 (1) 0.09 1.44 (x0.23 to 3.11)
Toronto Caucasian x1.24 (1) 0.21 x0.59 (x1.54 to 0.35)
Vienna* – – –
LR test
(x2[(Log L model B)x
(Log L model A)]
12.46 (2) 0.002
A-A, African-American ; LR, likelihood ratio.
* Dropped due to collinearity.
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response variable was TD status and the predictors
evaluated were age, gender and T102C/C genotype,
the LR test for the T102C/C genotype was again
signiﬁcant in the older (x2=12.93, d.f. 1, p=0.0003)
but not the younger patients (x2=1.15, d.f. 1, p=0.28).
The interaction between age and the T102C genotype
was not signiﬁcant suggesting that the underlying
model to explain the eﬀect of T102C genotype in the
old vs. the young group is a conditional eﬀect of
T102C related to age rather than a multiplicative eﬀect.
Figure 1 shows the frequency of 102C allele carriers in
the younger and older patients with and without TD.
Speciﬁcity of HTR2A polymorphism as a risk
factor for non-orofacial TD
We examined whether the HTR2A T102C polymorph-
ism is diﬀerentially related to orofacial dyskinesia as
opposed to dyskinesia aﬀecting the limbs or trunk
(non-orofacial dyskinesia) because of a preliminary
Table 5.Multinomial logistic regression analysis for variables predicting tardive dyskinesia phenotype in patients from
the six groups
Null model Log L=x427.64 LR x2 p
Model A Log L=0–403.44 LR x2 (d.f. 3)=48.40 p<0.0001
Variables OR S.E. 95% CI Z P>|z|
Age 3.06 0.67 1.99–4.72 5.08 <0.001
Sex 1.19 0.21 0.82–1.70 0.94 0.34
T102C genotypes 0.64 0.08 0.49–0.84 x3.32 0.001
Model B Log L=x409.05 LR x2 (d.f. 2)=37.17 p<0.0001
Variables OR S.E. 95% CI Z P>|z|
Age 3.11 0.68 2.02–4.78 5.17 <0.001
Sex 1.15 0.21 0.83–1.71 – 1.64
LR test LR x2 (d.f. 1)=11.23 p=0.0008
(x2[(Log L Model B)x(Log L Model A)]
LR, Likelihood ratio ; OR, odds ratio ; CI, conﬁdence interval.
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Figure 1. Frequency of 102C allele carriers (T/C heterozygotes and C/C homozygotes) in (a) younger patients (f47 yr) with
(Y-TD) (n=96) and without TD (N-TD) (n=215) and (b) in older patients Y-TD (n=159) and N-TD (n=164). Likelihood ratio test
for TD status predicting T102C/C allele carrier status in younger patients (f47 yr) : x2=0.18, d.f. 2, p=0.60 ; in older patients
(>47 years) : x2=10.16, d.f. 1, p=0.001.%, N-TD;&, Y-TD.
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observation by the Milan group (Macciardi et al., 1997)
that the T102C polymorphism was not related to TD in
an overall way but was related to limb dyskinesia. In
the data from three of the ﬁve centres (Jerusalem,
Milan and Singapore) separate TD ratings were avail-
able for orofacial, limb and trunk dyskinesia, accord-
ing to the Schooler and Kane criteria (Schooler and
Kane, 1982). Because of the rarity of trunk dyskinesia
(only 13 cases in all three groups and only three cases
in patients without concomitant orofacial TD), patients
with limb or trunk dyskinesia were combined into a
single non-orofacial TD group. We examined the
contribution of the T102C genotype to susceptibility
to non-orofacial TD by examining patients with non-
orofacial TD (n=31) and patients without TD (n=255)
separately, excluding patients with concomitant
orofacial TD (n=34) from the non-orofacial TD group.
A signiﬁcant eﬀect of the T102C genotype was ob-
served in the non-orofacial TD group only (Global test :
x2=15.0, d.f. 2, p=0.001). For C/C vs. T/T (x2=14.5,
d.f. 1, p=0.0001) ; for T/C vs. T/T (x2=1.98, d.f. 1, p=
0.16). Non-orofacial TD (in the absence of orofacial TD)
was almost exclusively observed in the patients older
than 47 yr (29 out of 31 patients with non-orofacial TD)
and the eﬀect was signiﬁcant in this group alone
when compared to the older patients without TD.
Performing the opposite analysis we compared pa-
tients with orofacial TD (n=100) to patients without
TD (n=255), excluding patients with concomitant
non-orofacial TD (n=34) from the group without
TD. In this analysis there was no eﬀect of the T102C
genotype in patients with orofacial TD compared to
the patients without TD (x2=4.65, d.f. 2, p=0.1).
Figure 2 shows the proportion of 102C allele
carriers and non-carriers with non-orofacial TD and
without TD.
Relationship of HTR2A polymorphism to severity of
dyskinetic movements
In addition to classifying TD status in a dichotomous
fashion we performed analyses of the relationship of
HTR2A T102C to abnormal involuntary movement as
a continuous variable in the four groups that had
AIMS ratings (Jerusalem, Singapore, Toronto A-A and
Toronto Caucasians). In an ANCOVA, AIMS total
score was the dependent variable ; group, gender and
T102C/C allele carrier status were the independent
variables and age was a covariate. There were signiﬁ-
cant main eﬀects of group (F=35.7, d.f. 3, p<0.0001),
T102C allele carrier status (F=5.2, d.f. 1, p=0.023) and
of the covariate age (F=31.8, d.f. 1, p<0.0001) but
not of gender. The grouprallele interaction was not
signiﬁcant (F=2.02, d.f. 3, p=0.11). The same elements
were included in a second ANCOVA except that the
T102C genotype was substituted for T102C/C allele
carrier status. In this model, the eﬀects of group
(F=30.6, d.f. 3, p<0.0001), T102C genotype (F=3.61,
d.f. 2, p=0.028) and of the covariate age (F=31.1, d.f. 1,
p<0.0001) but not gender were again signiﬁcant.
There was no grouprgenotype interaction (F=1.19,
d.f. 3, p=0.31). Post-hoc comparison with a Scheﬀe´ test
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Figure 2. Frequency of 102C allele carriers (T/C heterozygotes and C/C homozygotes) in (a) patients with (Y-TD) (n=100)
and without orofacial TD (n=255), excluding patients with concomitant non-orofacial TD (n=34) from the group without TD
and (b) in patients with (n=31) and without non-orofacial TD (n=255), excluding patients with concomitant orofacial TD
(n=34) from the non-orofacial TD group. Likelihood ratio test for TD status predicting T102C/C allele carrier status in patients
with orofacial TD: x2=2.1, d.f. 1, p=0.15 ; in patients with non-orofacial TD: x2=5.10, d.f. 1, p=0.02.%, N-TD;&, Y-TD.
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of adjusted mean AIMS total scores (Figure 3) showed
signiﬁcantly higher scores for the C/C vs. T/C
(p=0.001) and C/C vs. T/T (p<0.0001) genotypes.
Meta-analysis
Figure 4 shows the results of the meta-analysis and
presents the observed distribution of odds ratios for
TD among carriers of the T102C/C allele (T/C hetero-
zygotes and C/C homozygotes) in the six groups
included in the pooled analysis (Toronto A-A
excluded) and in an additional published report
(Herken et al., 2003). The Mantel–Haenszel (M-H)
pooled odds ratio (OR) across all the available data
was 1.64 (95% CI 1.17–2.32, x2=8.30, d.f. 1, p=0.004),
pointing to a small but signiﬁcant eﬀect of the HTR2A
T102C/C allele as a risk factor for TD. There was no
evidence for heterogeneity (x2=7.17, d.f. 5, p=0.21).
The meta-analysis was also signiﬁcant with the
Toronto A-A patients included (OR 1.67, 95% CI
1.19–2.36 ; x2=9.23, d.f. 1, p=0.002) but the 95% CI of
the A-A group individually was exceedingly large
(0.27–144.70, OR 6.30), well outside the 95% CI limits
of the groups combined.
Comment
HTR2A and modiﬁcation of the propensity to
express TD
The pooled analysis of 635 patients reported here
demonstrated a small but signiﬁcant increase of risk
for TD in patients with schizophrenia who carry the C
allele of the HTR2A T102C polymorphism, over and
above the potential confounding eﬀects of population
group, age and gender. A meta-analysis, which in-
cluded the results of a published paper that was not
part of the pooled analysis supported this ﬁnding with
an odds ratio of 1.64. We did not ﬁnd an eﬀect of the
His452Tyr polymorphism considered alone. However,
the joint contribution of T102C and His452Tyr was
signiﬁcant. While this eﬀect could be carried by the
strong eﬀect of T102C, the p value of the two-way
haplotype seems to suggest that the combination of the
two SNPs is in fact greater than T102C alone. An ex-
planation for the non-detectable eﬀect of His452Tyr
alone might be the low minor allele frequency in sev-
eral of the groups, which would require much larger
samples for the identiﬁcation of an association.
Limitations of the study must be borne in mind.
Evaluations of TD were conducted by diﬀerent clin-
icians in diﬀerent centres. While inter-rater reliability
was achieved within centres, this was not the case
between centres. Moreover, diﬀerent rating scales
were used to rate abnormal involuntary movements as
a basis for applying the RDC-TD. These limitations are
inevitable in a post-hoc analysis of data collected in
diﬀerent centres. Nevertheless, there was standardi-
zation in applying the RDC-TD, and also, the inclusion
of group as a confounding variable in the logistic re-
gression controls for this problem to a certain extent.
Data were not available from all the centres on the
type of antipsychotic drugs that the patients were
administered nor on dose and duration of use. These
are potentially important variables and our ﬁndings
must be considered in this context. A further limi-
tation is that in all the centres the diagnosis of TD was
based on a single assessment. Abnormal involuntary
movements may ﬂuctuate over time and the diagnosis
of TD in the sample must, therefore, be considered to
be at a ‘possible’ level according to the RDC-TD
(Schooler and Kane, 1982). Genotyping was done in
diﬀerent laboratories ; however, methods are standard
and the margin of error small. We did not correct
statistical analyses for multiple testing since it is
not clear that the two SNPs examined should be
regarded as independent in that they are located in
the same gene and are in LD. The same consideration
of non-independence may be applicable to the two
subsidiary phenotypes that we examined (age eﬀect
and body region speciﬁcity). However, the signiﬁ-
cance levels are such that in almost all cases the p value
would remain signiﬁcant even after correction.
The HTR2A T102C polymorphism is an intronic
variant that does not code for a change in the structure
of the receptor protein. It is in close LD with an
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Figure 3. Adjusted mean AIMS total scores by T102C
genotype (derived from ANCOVA with group, gender and
T102C genotype as independent variables and age as
covariate). Bars show standard error of the mean. ANCOVA
results given in the text. By post-hoc Scheﬀe´ test : C/C vs.
T/C genotype, p=0.001 ; C/C vs. T/T genotype, p<0.0001.
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A-1438G polymorphism in the HTR2A promoter
(Basile et al., 2001 ; Segman et al., 2001) that was found
by Segman et al. (2001) to be associated with TD. The
silent T102C site could reﬂect the impact of the
promoter site through LD. However, there is evidence
that the T102C polymorphism may directly aﬀect
expression of 5-HT2A mRNA and protein (Polesskaya
and Sokolov, 2002) and cortical ketanserin binding
(Turecki et al., 1999) although the results of other
studies are variable (Kouzmenko et al., 1999).
While the focus of the current study was on HTR2A
as a risk factor for TD, an alternative explanation is
possible. A small but signiﬁcant contribution of T102C
and more recently A-1438G to risk for schizophrenia
has been reported although not consistently (Hawi
et al., 1997 ; Lohmueller et al., 2003; Shinkai et al., 1998 ;
Spurlock et al., 1998 ; Williams et al., 1997) and also
association of the T102C polymorphism with response
to clozapine (Arranz et al., 1998) not replicated in other
studies (Malhotra et al., 1996 ; Masellis et al., 1998).
The HTR2A T102C polymorphism may be a genetic
marker for a subtype of schizophrenia that is char-
acterized by increased susceptibility to TD or reduced
responsiveness to antipsychotic drugs (Chakos et al.,
1996). The latter situation would result in patients
receiving higher doses of antipsychotics for longer
periods, thus being exposed to increased risk for TD
on this basis. This explanation would account for the
reported association of the polymorphism with
schizophrenia, clozapine response and TD in diﬀerent
studies. Studies that focus on a reﬁned phenotype that
includes drug responsiveness are needed.
Age-related association of HTR2A with TD
The inﬂuence of age on the association of the HTR2A
polymorphism with TD is an intriguing aspect of the
present study. Segman and Lerer (2002b) re-analysed
their data for three polymorphisms that were associ-
ated with TD in their sample. For two serotonin
receptor polymorphisms,HTR2C-Cys23Ser andHTR2A-
T102C, but not for DRD3, there was a signiﬁcant eﬀect
on AIMS scores only in subjects o47 yr. Segman and
Lerer (2002b) suggested that genetically based varia-
tions in receptors might become functionally relevant
at an older age when receptor reserve is reduced
below a critical threshold for reasons related to the
ageing process (Versijpt et al., 2003). Another possible
explanation is that older patients will generally have
been exposed to antipsychotic drugs for a longer
period. However, Segman and Lerer (2002b) con-
trolled for years of exposure and found that the age
eﬀect on the genetic associations that they observed
remained signiﬁcant. Of the four published studies on
the relationship of HTR2A T102C to TD, in the two that
found an association the mean age of the subjects was
>50 yr (Segman et al., 2001 ; Tan et al., 2001) and in the
two which did not ﬁnd an association the mean age
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Figure 4. Results of meta-analysis showing the odds ratios (OR) and 95% conﬁdence intervals (CI) for TD among carriers of
the T102C/C allele (T/C heterozygotes and C/C homozygotes) in six of the groups included in the pooled analysis (Toronto
A-A excluded) and in an additional published report (Herken et al., 2003). Mantel–Haenszel pooled OR=1.64 (95% CI
1.17–2.32 ; x2=8.30, d.f. 1, p=0.004).
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of the subjects was<35 yr (Basile et al., 2001 ; Herken
et al., 2003) (Table 1). In the present study, the
hypothesis of Segman andLerer (2002b)was conﬁrmed
in a large sample of patients. HTR2A T102C genotype
was signiﬁcantly associated with TD in the older
patients only (>47 yr). These ﬁndings have important
implications for the design and interpretation of
pharmacogenetic studies in psychiatry. If the increase
in risk conferred by a genetic variant is manifested
primarily in older patients, studies conﬁned to younger
samples could lead to its unwarranted exclusion. In
developing a pharmacogenetic test the age relatedness
of genetic variants included would need to be taken
into account. The same would apply to gender-related
genetic variants ; while these have not been identiﬁed
for TD, they could exist for other pharmacogenetic
phenotypes.
Genetic reﬁnement of the TD phenotype
Whereas TD is usually regarded as a unitary entity, its
clinical manifestations and course show considerable
heterogeneity. Previous studies have described two
major subtypes with predominantly orofacial or limb-
truncal presentations (Gureje, 1988; Muscettola et al.,
1999 ; Paulsen et al., 1996). Distinct clinical and demo-
graphic risk factors have been reported to associate
with these subtypes (Gureje, 1988 ; Muscettola et al.,
1999 ; Paulsen et al., 1996). Our results point to the
possibility that genetic variability in the 5-HT2A
receptor may diﬀerentially modulate the risk for
these TD subtypes with a speciﬁc emphasis on the
non-orofacial subtype.
Implications for the pharmacogenetics of TD
Case-control designs require large samples if they are
to identify and in particular replicate small gene
eﬀects and identify interactions among genes.
Therefore, it is frequently necessary to pool samples
from diﬀerent centres. While increasing power, this
can lead to spurious results if allele frequencies for
the genes being studied vary among the populations.
On the other hand, there is a distinct advantage to
studying pharmacogenetic issues across populations
so that it can be determined to what extent ﬁndings are
generally applicable. In the current analysis, we
applied a statistical approach, logistic regression, in
order to address the potentially confounding eﬀects of
population origin and also those of age and gender.
Previously, Lerer et al. (2001) applied this approach
to an analysis of the 5-HT2C receptor gene in large
samples of patients with recurrent major depression
(MDD) bipolar disorder (BPD) and in their analysis
of the DRD3 Ser9Gly polymorphism in relation to TD
(Lerer et al., 2002).
The results of the present study support an asso-
ciation of the T102C polymorphism and T102C-
His452Tyr haplotypes in the 5-HT2A receptor gene
with TD that is more strongly manifested in older
patients and in patients with non-orofacial (limb-
truncal) TD. In itself, this identiﬁed risk factor has low
predictive value and does not have clinical utility.
It should be considered in the context of a panel of
genetic polymorphisms that have been associated with
TD such as the Ser9Gly polymorphism in DRD3 (Lerer
et al., 2002) and the 5-HT2C receptor gene (HTR2C)
(Segman et al., 2000 ; Zhang et al., 2002). While the
individual contribution of each polymorphism to the
risk for TD is small, association of this complex pheno-
type with several genes is consistent with a polygenic
basis. The potential for developing a pharmacogenetic
test based on a combination of risk alleles is feasible
once a suﬃcient number of such variants have
been identiﬁed. Such a test would need to take into
account complex interactions among diﬀerent variants
(Segman et al., 2002 ; Zhang et al., 2003) as well as the
contribution of variables such as age, gender and
ethnic origin. Signiﬁcant association with TD of two
genes across populations – DRD3 in our previous
study (Lerer et al., 2002) and HTR2A in this paper – is
an important step in the direction of establishing a
pharmacogenetic test for susceptibility to TD.
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